Drug Profile


Alternative Names: PLK-1SNALP; PLK1-LNP; TKM-080301; TKM-PLK1

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Polo-like kinase 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatocellular carcinoma

Highest Development Phases

  • Phase I/II Adrenocortical carcinoma; Hepatocellular carcinoma; Neuroendocrine tumours
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 29 Nov 2016 Additional efficacy and adverse events data from a phase I/II trial in Hepatocellular carcinoma presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR - 2016)
  • 19 Jul 2016 TKM PLK1 is available for licensing as of 19 Jul 2016.
  • 19 Jul 2016 Efficacy and adverse events data from a phase I/II trial in Hepatocellular carcinoma released by Arbutus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top